

## RESEARCH ARTICLE

[View Article Online](#)  
[View Journal](#)

Cite this: DOI: 10.1039/c8md00413g

# Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors†

Xinyu Li,<sup>‡</sup> Binyu Shi,<sup>‡</sup> Yu Teng, Yu Cheng, Huizhu Yang, Jiurong Li, Lianjian Wang, Siying He, Qidong You and Hua Xiang \*

BTK is an effective target for the treatment of B-cell malignant tumors and autoimmune diseases. In this work, a series of 2-phenyl pyrimidine derivatives were prepared and their preliminary *in vitro* activities on B-cell leukemia cells as well as the BTK enzyme were determined. The results showed that compound **11g** displayed the best inhibitory activity on BTK with an inhibition rate of 82.76% at 100 nM and excellent anti-proliferation activity on three B-cell leukemia lines ( $IC_{50}$  = 3.66  $\mu$ M, 6.98  $\mu$ M, and 5.39  $\mu$ M against HL60, Raji and Ramos, respectively). Besides, the flow cytometry analysis results indicated that **11g** inhibited the proliferation of the Raji cells in a dose- and time-dependent manner, and blocked the Ramos cells at the G0/G1 phase, which is in accordance with the positive control ibrutinib. The mechanism investigation demonstrated that **11g** could inhibit the phosphorylation of BTK and its downstream substrate phospholipase  $\gamma$ 2 (PLC $\gamma$ 2). All these results showed that **11g** was a promising lead compound that merited further optimization as a novel class of BTK inhibitor for the treatment of B-cell lymphoblastic leukemia.

Received 29th August 2018,  
Accepted 23rd December 2018

DOI: 10.1039/c8md00413g

[rsc.li/medchemcomm](http://rsc.li/medchemcomm)

## Introduction

Bruton's tyrosine kinase (BTK) is a member of the TEC family of non-receptor tyrosine kinase which is predominantly expressed in all hematopoietic cells except plasma and T cells.<sup>1</sup> It is a crucial kinase in the B-cell receptor (BCR) signaling pathway.<sup>2,3</sup> The overexpression of BTK usually causes severe leukemia and B-cell-related lymphoma. Therefore, the development of drug molecules targeting BTK has become an attractive therapeutic approach.

Since BTK was discovered in the 1990s,<sup>4</sup> many small-molecule BTK inhibitors have been developed. Based on their binding mode with BTK, researchers found that the non-catalytic cysteine (Cys481) residue in the extended hinge region is the key binding site for the irreversible BTK inhibitors such as ibrutinib (approved), acalabrutinib (approved), ONO-4059 (phase II), spebrutinib (phase II) and HM71224 (phase II) (Fig. 1). They generally contain a pyrimidine core with an acrylamide group which can bind to the Cys481 residue covalently as a Michael acceptor and irreversibly inhibit BTK.<sup>5,6</sup> Ibrutinib, a highly potent oral small-molecule inhibitor, is a

first-generation BTK inhibitor. It was approved by the FDA for the treatment of mantle cell lymphoma (MCL) in 2013, and was further used as a monotherapy to treat chronic lymphocytic leukaemia (CLL) in 2014.<sup>7</sup> In 2015 and 2017, ibrutinib was approved for the treatment of Waldenstrom's macroglobulinaemia (WM) and chronic graft-versus-host disease (cGVHD), respectively.<sup>8</sup> Despite the great success achieved by ibrutinib, its off-target effect also leads to the clinically observed adverse effects including arthralgias, rash, atrial fibrillation, diarrhea, ecchymosis and massive hemorrhage due to ibrutinib's irreversible binding with other kinases such as epidermal growth factor receptor (EGFR), ITK, and TEC.<sup>9</sup> Moreover, most of the BTK inhibitors mentioned above have been reported to have limited efficacy and strong side effects. Hence, there is still an increasing need to discover novel BTK inhibitors which could be developed into therapeutic candidates for the treatment of B-cell malignancies.<sup>10</sup>

Previous structure and activity relationship (SAR) explorations showed that a pyrimidine core and a typical *N*-phenylacrylamide pharmacophore are important for novel inhibitors to bind with BTK. CGI-560 (Fig. 1) was obtained by screening from compound libraries and exhibited modest BTK potency (half-maximal inhibitory concentration ( $IC_{50}$ ) = 400 nM) but promising selectivity (>ten-fold) over an initial panel of 16 kinases.<sup>11</sup> Based on this, we hope to splice some pharmacophores on this skeleton to improve the selectivity as well as inhibition for BTK, and then obtain the novel BTK

Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China. E-mail: [xianghua@cpu.edu.cn](mailto:xianghua@cpu.edu.cn);

Fax: +86 025 83271096; Tel: +86 025 83271096

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8md00413g

‡ These authors have the same contribution to this paper.




Fig. 1 Chemical structures of the reported BTK inhibitors.

inhibitor. First, we introduced the key acrylamide group and acyl side chain of the reported BTK ligand PLS-123 to substitute the side chains at the two ends of CGI-560. Moreover, Dan Zhao *et al.* reported the structural optimizations of diphenylpyrimidine derivatives based on spebrutinib, which showed that the chloro substituent at the C-5 position of the pyrimidine core is more favorable than the fluoro atom due to stronger hydrophobicity in the binding site.<sup>12</sup> So we introduced the chloro atom at the C-6 position after the skeleton transition. Finally, we design a series of 2-phenyl pyrimidine derivatives as novel potent BTK inhibitors which retain the

pyrimidine core and typical *N*-phenylacrylamide functionality (Fig. 2).

The syntheses of novel 2-phenyl pyrimidine 11a–11i are summarized in Scheme 1. 4-Nitrobenzaldehyde as the starting material was condensed with hydroxylamine hydrochloride under reflux to afford benzonitrile 2 which was transformed to compound 3 by reacting with ammonium chloride. The pyrimidine nucleus 4 was prepared through the condensation reaction of compound 3 and diethyl malonate, and then it was reacted with POCl<sub>3</sub> to produce the key intermediate 5 which was reduced by Fe





Fig. 2 Rational design strategy of our compounds.



**Scheme 1** Reagents and conditions: (a) hydroxylamine hydrochloride, DMSO, 100 °C, 0.5 h, 82.0%; (b) methanol, sodium methoxide, rt, 5 h; ammonium chloride, rt, 4 h, 97.0%; (c) ethanol, diethyl malonate, sodium methoxide, N<sub>2</sub>, reflux, 4 h, 87.4%; (d) POCl<sub>3</sub>, DMF, 100 °C, 8 h, 46.3%; (e) methanol: water (1:1), Fe, NH<sub>4</sub>Cl, 70 °C, 5 h, 60.7%; (f) DMF, acryloyl chloride, triethylamine, 0 °C, 1 h, 56.5%; (g) THF, triethylamine, different amines or phenylamine, 0 °C, 0.5 h, 91.5%; (h) methanol: water (1:1), Fe, NH<sub>4</sub>Cl, 70 °C, 0.5 h, 69.2%; (i) anhydrous dioxane, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 100 °C, 8 h, 20.5–34.0%.

to yield compound **6**. Substitution of compound **6** with acryloyl chloride generated compound **7**. On the other hand, 4-nitrobenzoyl chloride was reacted with different amines or phenylamine to provide compounds **9a–9j**, following a reduction reaction by Fe to get the different side chains (**10a–10i**). Finally, the Pd-catalyzed Buchwald–Hartwig amination of **7** with different side chains (**10a–10i**) afford target compounds **11a–11i**.

The activity against BTK of the synthesized molecules was evaluated using an ADP-Glo™ kinase assay system.<sup>13–15</sup> Three B-cell leukemia lines (Raji, HL60 and Ramos) which over-expressed the BTK enzyme were used for the cell proliferation evaluations through the MTT method. For comparison, ibrutinib was tested as the positive control. As shown in Table 1, most of our designed compounds showed good inhibition (>50%) against BTK. In particular, **11e**, **11g** and **11h** could strongly inhibit the BTK activity, which displayed 82.7–83.9% inhibition in contrast with that of ibrutinib (99.4%). The kinase-based test results confirmed that the large-size substituent groups (analogues **11d**, **11e**, **11g** and **11h**) are more favorable than the small-size groups (analogues **11a–11c**). It was not beneficial for the inhibition with the di-substituted arylamine as R (analogues **11f** and **11i**). As a global observation, most of the target compounds inhibit the proliferations of these leukemia lines at concentrations ranging from 1 to 20 μmol L<sup>−1</sup>. Compound **11g**, which has a


3-methyl phenylcarbamoyl substituent at the C-4 aniline moiety of the pyrimidine core, possessed the most promising anti-proliferative activity on the three leukemia lines. Particularly, it is higher than ibrutinib for its activity against the Raji cells (IC<sub>50</sub> = 6.98 μM and 14.5 μM, respectively), suggesting that a new action mechanism for them to be produced interferes with the B-cell lymphoblastic leukemia cells. Nevertheless, the fluorine-substituted and methoxy-substituted C-4 aniline moieties almost lost their activity against the B-cell leukemia lines (IC<sub>50</sub> not determined) in spite of their high capability to inhibit the BTK activity. We speculated that the low water solubility might be the main reason for their low anti-B lymphoma cell activity. In contrast, **11b**, **11c**, **11d** and **11f**, which only possessed moderate activity against BTK (Inh% = 40–60%), were able to strongly inhibit the proliferation of the three leukemia lines with an IC<sub>50</sub> value ranging from 1 to 20 μmol L<sup>−1</sup>.

Additionally, the effect of treatment time and drug concentration was further explored for compound **11g** on Raji cell viability. As a result, all of these compounds inhibited the proliferation of the Raji cells in a dose- and time-dependent manner, and almost completely blocked the Raji cells (90%) at a concentration of 40 μM after 72 h (Fig. 3). Moreover, **11g** displayed better anti-proliferation activity than positive control ibrutinib in a time-dependent manner at a concentration of 5 μM.

**Table 1** SAR of the synthesized compounds

Compound	R	HL60 IC <sub>50</sub> (μM)	Raji IC <sub>50</sub> (μM)	Ramos IC <sub>50</sub> (μM)	BTK <sup>a</sup> Inh% at 100 nm
11a		>50	42.9	>50	ND <sup>b</sup>
11b		9.34	12.5	11.2	40.3
11c		15.8	19.2	10.4	59.8
11d		5.94	14.7	7.24	60.7
11e		ND	ND	ND	83.9
11f		4.79	9.36	6.18	56.5
11g		3.66	6.98	5.39	82.7
11h		ND	ND	ND	83.9
11i		14.9	20.9	16.8	ND
Ibrutinib		3.57	14.5	2.31	99.4

<sup>a</sup> Percentage inhibition rate of each compound on BTK at 100 nM was measured using the ADP-Glo™ kinase assay system, shown as means of three experiments. <sup>b</sup> Not determined.

**Fig. 3** The effects of treatment time and drug concentration for compound **11g** on Raji cell viability.

Flow cytometry assays by incubating Ramos cells with 5 μM compound **11g** for 48 h were also performed. Excitingly, the result shown in Fig. 4 indicate that inhibitor **11g** induced Ramos cell apoptosis with 38.5% which is higher than the reference agent ibrutinib (7.83%) at the concentration of 5 μM. In addition, to investigate the anti-proliferative mechanism of our designed compounds on B-cell leukemia cells, we further evaluated the effect of the most active inhibitor

**11g** on the distribution of the Ramos cells in the cell cycle with ibrutinib as the positive control. As shown in Fig. 5, after incubation with 5 μmol L<sup>-1</sup> inhibitor **11g** and ibrutinib for 48 h, the DNA contents of the Ramos cells were 36.27% and 30.5% in the G0/G1 phase, respectively. Apparently, the newly synthesized molecule **11g** blocked the Ramos cells at the G0/G1 phase, which is in accordance with the reference compound ibrutinib.




Fig. 4 Compound **11g** induced Ramos cell apoptosis *in vitro*. The cells were incubated at the concentration of 5  $\mu$ M for 48 h, and DMSO and ibrutinib were treated as the blank and positive controls, respectively.





Fig. 5 Cell cycle analysis of the treatment of the Ramos cells with compound **11g** at the concentration of 5  $\mu$ M for 48 h, and DMSO and ibrutinib were treated as the blank and positive controls, respectively.

The BCR signaling pathway is relevant to several severe leukemias and lymphomas. The BCR is the first aggregate with CD79 which contains immunoreceptor tyrosine-based activation motifs (ITAM). After that, ITAM are phosphorylated primarily by Src-family tyrosine kinases, such as Lyn. The Src-family kinases and phosphorylated ITAM serve as a scaffolding platform for engaging and activating SH2 domains containing kinases, including Syk, which leads to BTK being recruited to the cell membrane and phosphorylated in its SH2 domain. The activated BTK then phos-

phorylates its substrate phospholipase $\gamma$ 2 (PLC $\gamma$ 2), leading to activation of the downstream signaling pathways, such as NF- $\kappa$ B and STAT3.<sup>16</sup> In fact, over-expression of BTK may cause the disorder of the B-cell signaling pathway, leading to B-cell malignancies and autoimmune diseases.<sup>17</sup> Thus we performed the western blotting assay to detect the phosphorylation of BTK and its substrate PLC $\gamma$ 2. The result showed that **11g** could inhibit their phosphorylation, though it is weaker than the positive control ibrutinib (Fig. 6).





**Fig. 6** Effect of **11g** on BTK and PLCγ2 phosphorylation in the Ramos cells with ibrutinib as the positive control.

## Conclusions

In summary, we designed and synthesized a series of 2-phenyl pyrimidine derivatives based on the skeleton of highly selective but modestly potent BTK inhibitor CGI-560, then a variety of pharmacophores were used to improve their BTK inhibition. Most of them exhibited good inhibitory activities in both cellular and enzymatic assays. In particular, compound **11g** with a 3-methyl phenylcarbamoyl substituent at the C-4 aniline moiety of the pyrimidine core displayed stronger activity than the positive control (ibrutinib) against Raji cells. The further mechanism study showed that compound **11g** could not only induce cell cycle arrest and apoptosis in B-cell leukemia lines but also inhibit the phosphorylation of BTK and its substrate PLCγ2. Overall, **11g** could serve as a promising highly selective lead candidate for further study.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We are grateful to the Program of Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, the postgraduate innovation fund of Huahai medical corporation and the college students' innovation and entrepreneurship training program (201810316104) for the financial support of this research.

## Notes and references

- G. V. De Lucca, Q. Shi, Q. Liu, D. G. Batt, M. Beaudoin Bertrand, R. Rampulla, A. Mathur, L. Discenza, C. D'Arienzo, J. Dai, M. Obermeier, R. Vickery, Y. Zhang, Z. Yang, P. Marathe, A. J. Tebben, J. K. Muckelbauer, C. J. Chang, H. Zhang, K. Gillooly, T. Taylor, M. A. Pattoli, S. Skala, D. W. Kukral, K. W. McIntyre, L. Salter-Cid, A. Fura, J. R. Burke, J. C. Barrish, P. H. Carter and J. A. Tino, *J. Med. Chem.*, 2016, **59**, 7915–7935.
- W. N. Khan, *Immunol. Res.*, 2001, **23**, 147–156.
- A. B. Satterthwaite and O. N. Witte, *Immunol. Rev.*, 2010, **175**, 120–127.
- J. J. Buggy and L. Elias, *Int. Rev. Immunol.*, 2012, **31**, 119–132.
- M. S. Cohen, C. Zhang, K. M. Shokat and J. Taunton, *Science*, 2005, **308**, 1318–1321.
- Y. Ge, H. Yang, C. Wang, Q. Meng, L. Li, H. Sun, Y. Zhen, K. Liu, Y. Li and X. Ma, *Bioorg. Med. Chem.*, 2017, **25**, 765–772.
- M. Sachdeva and S. Dhingra, *Int. J. Appl. Basic Med. Res.*, 2015, **5**, 54–57.
- C. Liang, D. Tian, X. Ren, S. Ding, M. Jia, M. Xin and S. Thareja, *Eur. J. Med. Chem.*, 2018, 315–326.
- Y. Xue, P. R. Song, Z. L. Song, A. L. Wang, L. J. Tong, M. Y. Geng, J. Ding, Q. S. Liu, L. P. Sun, H. Xie and A. Zhang, *J. Med. Chem.*, 2018, **61**, 4608–4627.
- H. Chen, P. Song, Y. Diao, Y. Hao, D. Dou, W. Wang, X. Fang, Y. Wang, Z. Zhao, J. Ding, H. Li, H. Xie and Y. Xu, *MedChemComm*, 2018, **9**, 697–704.
- P. J. Di, T. Huang, M. Balazs, J. Barbosa, K. H. Barck, B. J. Bravo, R. A. Carano, J. Darrow, D. R. Davies and L. E. Deforge, *Nat. Chem. Biol.*, 2011, **7**, 41–50.
- D. Zhao, S. Huang, M. Qu, C. Wang, Z. Liu, Z. Li, J. Peng, K. Liu, Y. Li and X. Ma, *Eur. J. Med. Chem.*, 2017, **126**, 444–455.
- R. Somberg, B. Pferdehirt and K. Kupcho, *Cell*, 2003.
- H. Zegzouti, M. Zdanovskaia, K. Hsiao and S. A. Goueli, *Assay Drug Dev. Technol.*, 2009, **7**, 560.
- J. V. Cizdziel, C. Tolbert and G. Brown, *Spectrochim. Acta, Part B*, 2010, **65**, 176–180.
- Y. Wang, L. L. Zhang, R. E. Champlin and M. L. Wang, *Clin. Pharmacol. Ther.*, 2015, **97**, 455–468.
- A. B. Satterthwaite and O. N. Witte, *Immunol. Rev.*, 2000, **175**, 120–127.